Advanced search
Publication Cover
Modern Rheumatology Volume 22, 2012 - Issue 2
Journal homepage
51
Views
5
CrossRef citations to date
0
Altmetric
ORIGINAL ARTICLE

Structural damages disturb functional improvement in patients with rheumatoid arthritis treated with etanercept

Yoshiya TanakaThe First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, 1-1 Iseigaoka, Yahata-nishi, Kitakyushu 807-8555, JapanCorrespondence[email protected]
,
Hisashi YamanakaInstitute of Rheumatology, Tokyo Women’s Medical University, Tokyo, Japan
,
Kazuyoshi SaitoThe First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, 1-1 Iseigaoka, Yahata-nishi, Kitakyushu 807-8555, Japan
,
Shigeru IwataThe First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, 1-1 Iseigaoka, Yahata-nishi, Kitakyushu 807-8555, Japan
,
Ippei MiyagawaThe First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, 1-1 Iseigaoka, Yahata-nishi, Kitakyushu 807-8555, Japan
,
Yohei SetoInstitute of Rheumatology, Tokyo Women’s Medical University, Tokyo, Japan
,
Shigeki MomoharaInstitute of Rheumatology, Tokyo Women’s Medical University, Tokyo, Japan
,
Hayato NagasawaDivision of Rheumatology and Clinical Immunology, Saitama Medical Center, Saitama Medical University, Kawagoe, Japan
,
Hideto KamedaDivision of Rheumatology and Clinical Immunology, Department of Internal Medicine, Faculty of Medicine, Keio University, Tokyo, Japan
,
Yuko KanekoDivision of Rheumatology and Clinical Immunology, Department of Internal Medicine, Faculty of Medicine, Keio University, Tokyo, Japan
,
Keisuke IzumiDivision of Rheumatology and Clinical Immunology, Department of Internal Medicine, Faculty of Medicine, Keio University, Tokyo, Japan
,
Koichi AmanoDivision of Rheumatology and Clinical Immunology, Saitama Medical Center, Saitama Medical University, Kawagoe, Japan
&
Tsutomu TakeuchiDivision of Rheumatology and Clinical Immunology, Department of Internal Medicine, Faculty of Medicine, Keio University, Tokyo, Japan
 show all
Pages 186-194 | Received 20 May 2011, Accepted 01 Aug 2011, Published online: 02 Jan 2014

References

  • Scott DL, Wolfe F, Huizinga TW. Rheumatoid arthritis. Lancet. 2010;376:1094–108.
  • Klareskog L, Catrina Al, Paget S. Rheumatoid arthritis. Lancet. 2009;373:659–72.
  • Smolen JS, Landewé R, Breedveld FC, Dougados M, Emery P, et al. EULAR recommendations for the management of rheu-matoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis. 2010;69:964–75.
  • Nam JL, Winthrop KL, van Vollenhoven RF, Pavelka K, Valesini G, Hensor EM, Worthy G, Landewé R, Smolen JS, Emery P, Buch MH. Current evidence for the management of rheumatoid arthritis with biological disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommen-dations for the management of RA. Ann Rheum Dis. 2010;69:976–86.
  • Aletaha D, Neogi T, Silman AJ, et al. 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/ European League Against Rheumatism collaborative initiative. Ann Rheum Dis. 2010;69:1580–8.
  • Weinblatt ME, Kremer JM, Bankhurst AD, et al. A trial of eta-nercept, a recombinant tumor necrosis factor receptor: Fc fusion protein, in patients with rheumatoid arthritis receiving metho-trexate. N Engl J Med. 1999;340:253–9.
  • Bathon JM, Martin RW, Fleischmann RM, Tesser JR, Schiff MH, Keystone EC, et al. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med. 2000;343 :1586–93.
  • Klareskog L, van der Heijde D, de Jager JP, et al. Therapeutic effect of the combination of etanercept and methotrexate com-pared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet. 2004;363:675–81.
  • Emery P, Breedveld FC, Hall S, et al. Comparison of metho-trexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): a randomised, double-blind, parallel treat-ment trial. Lancet. 2008;372:375–82.
  • Koike T, Harigai M, Inokuma S, Inoue K, Ishiguro N, Ryu J, Takeuchi T, Tanaka Y, Yamanaka H, Fujii K, Freundlich B, Suzukawa M. Postmarketing surveillance of the safety and effec-tiveness of etanercept in Japan. J Rheumatol. 2009;36:898–906.
  • Weinblatt ME, Bathon JM, Kremer JM, Fleischmann RM, Schiff MH, Martin RW, Baumgartner SW, Park GS, Mancini EL, Genovese MC. Safety and efficacy of etanercept beyond 10 years of therapy in North American patients with early and long-standing rheumatoid arthritis. Arthritis Care Res (Hoboken). 2010;epub ahead of print.
  • Moreland LW, Weinblatt ME, Keystone EC, Kremer JM, Martin RW, Schiff MH, Whitmore JB, White BW. Etanercept treatment in adults with established rheumatoid arthritis: 7 years of clinical experience. J Rheumatol. 2006;33:854–61.
  • Schiff MH, Yu EB, Weinblatt ME, Moreland LW, Genovese MC, White B, Singh A, Chon Y, Woolley JM. Long-term experience with etanercept in the treatment of rheumatoid arthritis in elderly and younger patients: patient-reported outcomes from multiple controlled and open-label extension studies. Drugs Aging. 2006;23:167–78.
  • Arnett FC, Edworthy SM, Bloch DA, et al. The American Rheumatism Association 1987 revised criteria for the classifi cation of rheumatoid arthritis. Arthritis Rheum. 1988;31:315–24.
  • van der Heijde D. Radiographic progression in rheumatoid arthritis: does it reflect outcome? Does it reflect treatment? Ann Rheum Dis. 2001;60\(suppl 3):iii47–50.
  • van der Heijde D. How to read radiographs according to the Sharp/van der Heijde method. J Rheumatol. 2000;27:261–3.
  • Takeuchi T, Yamanaka H, Inoue E, Nagasawa H, Nawata M, Ikari K, Saito K, Sekiguchi N, Sato E, Kameda H, Iwata S, Mochizuki T, Amano K, Tanaka Y. Retrospective clinical study on the notable efficacy and related factors of infliximab therapy in a rheumatoid arthritis management group in Japan: one-year outcome of joint destruction (RECONFIRM-2 J). Mod Rheu-matol. 2008;18:447–54.
  • Smolen JS, Aletaha D, Grisar JC, Stamm TA, Sharp JT. Esti-mation of a numerical value for joint damage-related physical disability in rheumatoid arthritis clinical trials. Ann Rheum Dis. 2010;69:1058–64.
  • Aletaha D, Funovits J, Breedveld FC, Sharp J, Segurado 0, Smolen JS. Rheumatoid arthritis joint progression in sustained remission is determined by disease activity levels preceding the period of radiographic assessment. Arthritis Rheum. 2009;60: 1242–9.
  • Aletaha D, Funovits J, Smolen JS. Physical disability in rheu-matoid arthritis is associated with cartilage damage rather than bone destruction. Ann Rheum Dis. 2011;70:733–9.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.